hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06336057, orgStudyIdInfo id: RC31/23/0408, briefTitle: Mentalizating in Adults Suffering From Narcolepsy Type 1., acronym: NARCOMENTAL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: University Hospital, Toulouse, class: OTHER, descriptionModule briefSummary: The main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. Indeed, the hypothesis of this research is that mentalization could be impaired in narcoleptic patients., conditionsModule conditions: Narcolepsy Type 1, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Mentalization, outcomesModule primaryOutcomes measure: Comparison of mentalization abilities, in a population of patients with NT1 versus a control group., secondaryOutcomes measure: Comparison and description of mentalization abilities in a population of patients versus controls., secondaryOutcomes measure: Better characterization of the clinical impression of an altered subjective experience of the difficulties the patients are going through., secondaryOutcomes measure: Determination of the existence of a correlation between the time of appearance of the first symptoms and the initiation of treatment and the level of mentalization in NT1 patients, or not., secondaryOutcomes measure: Determination of the existence of a correlation between the age at the first symptoms of NT1 patients and mentalization abilities, or not., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre de compétence Narcolepsies et Hypersomnies rares, CHU de Toulouse, Hôpital Pierre-Paul Riquet, city: Toulouse, zip: 31059, country: France, contacts name: Rachel DEBS, Dr, role: CONTACT, phone: 05 61 77 94 88, email: debs.r@chu-toulouse.fr, geoPoint lat: 43.60426, lon: 1.44367, hasResults: False
protocolSection identificationModule nctId: NCT06336044, orgStudyIdInfo id: Taufiller/22, briefTitle: Pre-marketing Clinical Trial to Evaluate the Safety and Efficacy of the Filler of Hyaluronic Acid Recombinant Collagen, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Taumedika s.r.l., class: INDUSTRY, collaborators name: Nextrasearch S.r.l.s., descriptionModule briefSummary: Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 20 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events, conditionsModule conditions: Wrinkle, conditions: Scar, conditions: Laxity; Skin, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 20 patients will undergo skin characterists measurments at time 0 at +4weeks and at +16 weeks, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Karisma, outcomesModule primaryOutcomes measure: Safety: no adverse events, primaryOutcomes measure: Efficacy: change of wrinkles and scars, primaryOutcomes measure: Efficacy: change of wrinkles and scars, primaryOutcomes measure: Efficacy: change of wrinkles and scars, primaryOutcomes measure: Efficacy: change of wrinkles and scars, secondaryOutcomes measure: Duration of the efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336031, orgStudyIdInfo id: 30002163, briefTitle: Impact of Blood Phobia on Fainting Susceptibility, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Simon Fraser University, class: OTHER, descriptionModule briefSummary: The primary purpose of this study is to characterize cardiovascular autonomic function to emotional stimuli (blood-injection-injury phobia \[needle phobia\]) during an orthostatic (upright) challenge in individuals with and without known needle phobia. It is well established that emotional stress can produce hypotensive (low blood pressure) reactions. Interestingly, these hypotensive reactions to venipuncture (even with minimal blood drawn), insulin injections, finger sticks for blood sugar monitoring, dental care, and vaccinations can affect up to a quarter of adults and appear to be uniquely associated with blood-injection-injury phobia rather than other phobias. These hypotensive reactions can ultimately lead to a vasovagal syncope (fainting) response, and lead to increased avoidance of medical and dental procedures as a result of this phobia. Ultimately, this has severe implications on public health and places additional strain on the Canadian healthcare system. Currently, there is limited understanding surrounding the initiation of this response. Additionally, a comprehensive profile of cardiovascular autonomic function during exposure to provoking stimuli during orthostatic stress has not been captured in the literature. We will test individuals with and without blood-injection-injury phobia using our standard approach while exposing them to emotional stimuli., conditionsModule conditions: Syncope, Vasovagal, conditions: Blood, Injection, Injury Type Phobia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: blood-injection-injury (BII) phobia stimuli, interventions name: neutral stimuli, outcomesModule primaryOutcomes measure: Orthostatic Tolerance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Simon Fraser University, status: RECRUITING, city: Burnaby, state: British Columbia, zip: V5A 1S6, country: Canada, contacts name: Vera E Lucci, PhD, role: CONTACT, phone: 7787828560, email: vlucci@sfu.ca, contacts name: Victoria E Claydon, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 49.26636, lon: -122.95263, hasResults: False
protocolSection identificationModule nctId: NCT06336018, orgStudyIdInfo id: NN7535-7703, secondaryIdInfos id: U1111-1289-2466, type: OTHER, domain: World Health Organization (WHO), briefTitle: A Research Study on Etavopivat in Participants With and Without Liver Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2025-07-04, completionDateStruct date: 2025-07-04, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days., conditionsModule conditions: Liver Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Etavopivat, outcomesModule primaryOutcomes measure: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat), primaryOutcomes measure: Maximum observed etavopivat plasma concentration after a single dose (Cmax, etavopivat), secondaryOutcomes measure: Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration after a single dose (AUC0-last, etavopivat), secondaryOutcomes measure: Time to maximum observed etavopivat plasma concentration after a single dose (tmax, etavopivat), secondaryOutcomes measure: Terminal half-life for etavopivat after a single dose (t1/2, etavopivat), secondaryOutcomes measure: Apparent plasma clearance of etavopivat after a single dose (CL/Fetavopivat), secondaryOutcomes measure: Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values (Vz/Fetavopivat), secondaryOutcomes measure: Number of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Orlando Clinical Research Center, city: Orlando, state: Florida, zip: 32806, country: United States, geoPoint lat: 28.53834, lon: -81.37924, locations facility: Amer. Rrsch Corp-TX Liver Inst, city: San Antonio, state: Texas, zip: 78215, country: United States, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06336005, orgStudyIdInfo id: NN6022-7683, briefTitle: A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2024-10-17, completionDateStruct date: 2024-10-17, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases.The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine.Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.The study will last for about 10 months in total., conditionsModule conditions: Healthy Volunteers, conditions: Cardiometabolic Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Sponsor staff involved in the clinical trial is masked according to company standard procedures., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: NNC6022-0001, interventions name: Placebo (NNC6022-0001), outcomesModule primaryOutcomes measure: Number of treatment emergent adverse events (TEAE), secondaryOutcomes measure: AUC0-t, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose, secondaryOutcomes measure: AUC0-∞, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to infinity after a single dose, secondaryOutcomes measure: Cmax, SD; the maximum plasma concentration of NNC6022 0001 after a single dose, secondaryOutcomes measure: IL-1β, SD; ratio of <Timepoint> (time of the maximal plasma concentration of NNC6022 0001) to baseline, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: ICON - location Groningen, status: RECRUITING, city: Groningen, zip: 9728 NZ, country: Netherlands, geoPoint lat: 53.21917, lon: 6.56667, hasResults: False
protocolSection identificationModule nctId: NCT06335979, orgStudyIdInfo id: CPIT565B12101, secondaryIdInfos id: 2023-510025-14-00, type: OTHER, domain: EU CT, briefTitle: An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE)., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-16, primaryCompletionDateStruct date: 2028-08-23, completionDateStruct date: 2028-08-23, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Novartis Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE, conditionsModule conditions: Systemic Lupus Erythematosus, SLE, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: PIT565, outcomesModule primaryOutcomes measure: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs), secondaryOutcomes measure: Maximum Observed Blood Concentrations (Cmax), secondaryOutcomes measure: Time to Reach Maximum Blood Concentrations (Tmax), secondaryOutcomes measure: Presence/absence of Anti-drug Antibodies, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06335966, orgStudyIdInfo id: STUDY00025975, briefTitle: BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy, acronym: BEST-RPP, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2025-01-30, completionDateStruct date: 2025-01-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: OHSU Knight Cancer Institute, class: OTHER, collaborators name: Kuni Foundation, collaborators name: Oregon Health and Science University, descriptionModule briefSummary: Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon., conditionsModule conditions: Esophageal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Screening with swallowable esophageal cell-collection devices (SECD), outcomesModule primaryOutcomes measure: Feasibility of the use of a SECD: Number of providers who indicate likelihood of using SECD, primaryOutcomes measure: Feasibility of the use of SECD: Number of providers who indicate willingness to be trained and train clinic staff, primaryOutcomes measure: Feasibility of the use of SECD: Number of referrals, primaryOutcomes measure: Feasibility of the use of SECD: Number enrolled, primaryOutcomes measure: Patient acceptability: Number of interested patients who schedule an appointment to be screened, primaryOutcomes measure: Patient acceptability: Number of patients who come to their appointments, primaryOutcomes measure: Patient acceptability: Number of patients interested in being screened via SECD at other care centers, secondaryOutcomes measure: Access: time to full diagnostic work up for patients with positive SECD results, eligibilityModule sex: MALE, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: OHSU Knight Cancer Institute, status: RECRUITING, city: Portland, state: Oregon, zip: 97239, country: United States, contacts name: Laura Ferrara, MA, role: CONTACT, phone: 541-399-1139, contacts name: Fouad Otaki, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.52345, lon: -122.67621, hasResults: False
protocolSection identificationModule nctId: NCT06335953, orgStudyIdInfo id: IRB00418404, secondaryIdInfos id: U54AG063546, type: NIH, link: https://reporter.nih.gov/quickSearch/U54AG063546, briefTitle: ALIGN: Aligning Medications With What Matters Most (Demonstration), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, collaborators name: National Institute on Aging (NIA), descriptionModule briefSummary: The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of the person's goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored de-prescribing recommendations designed to be useful and actionable for the PCP.The investigators will compare the intervention group with the waitlist control group to see if there is a difference in the primary outcome, the proportion of patients who deprescribe at least one medication by 3 months., conditionsModule conditions: Polypharmacy, conditions: Alzheimer's Disease and Related Dementias, conditions: Mild Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 280, type: ESTIMATED, armsInterventionsModule interventions name: Pharmacist-led deprescribing intervention, outcomesModule primaryOutcomes measure: Proportion of patients who stop one or more medications, secondaryOutcomes measure: Proportion of patients who start one or more new medications, secondaryOutcomes measure: Proportion of patients who stop one or more potentially inappropriate medication (PIM), secondaryOutcomes measure: Total number of medications, otherOutcomes measure: Shared decision-making as assessed by CollaboRATE, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Johns Hopkins Bayview Medical Center, city: Baltimore, state: Maryland, zip: 21224, country: United States, contacts name: Ariel Green, MD, MPH, PhD, role: CONTACT, phone: 410-550-6733, email: ariel@jhmi.edu, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06335927, orgStudyIdInfo id: GWK2023-001, briefTitle: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-11, primaryCompletionDateStruct date: 2025-05-10, completionDateStruct date: 2026-05-10, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This study is a single-arm Phase II clinical trial aiming to evaluate the safety and efficacy of HAIC combined with Cadonilimab and Regorafenib as second-line treatment for unresectable intrahepatic cholangiocarcinoma.The study plans to enroll approximately 45 participants. All enrolled participants will receive continuous treatment: HAIC-Gemox: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles, Cadonilimab(6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W) until the investigator determines that there is no longer any clinical benefit (based on comprehensive assessment including RECIST v1.1 imaging evaluation and clinical condition), intolerable toxicity, initiation of new anti-tumor therapy, or meeting other criteria for treatment discontinuation, whichever occurs first., conditionsModule conditions: Intrahepatic Cholangiocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: HAIC-GEMOX+Cadonilimab+Regorafenib, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Hepatic Objective Response Rate (hORR), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Time to Response (TTR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Safety and tolerability, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Li Tan, role: CONTACT, phone: +8615800680751, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06335914, orgStudyIdInfo id: dualPET-mPC, secondaryIdInfos id: CAPCR: 23-5595, type: OTHER, domain: University Health Network, briefTitle: Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2029-03-04, completionDateStruct date: 2029-09-04, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: University Health Network, Toronto, class: OTHER, descriptionModule briefSummary: This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future., conditionsModule conditions: Advanced Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ga 68 PSMA-11 PET, interventions name: 18F-DCFPyL PET, interventions name: FDG PET, outcomesModule primaryOutcomes measure: Proportion of patients with high volume mCSPC having PSMA avid disease, secondaryOutcomes measure: Proportion of patients with PSMA-/FDG+ discordant lesions, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Princess Margaret Cancer Centre, city: Toronto, state: Ontario, zip: M5G 2M9, country: Canada, contacts name: Di (Maria) Jiang, M.D., role: CONTACT, phone: 416-946-4501, phoneExt: 4807, email: di.jiang@uhn.ca, contacts name: Di (Maria) Jiang, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False